Dear Reader, In 1918, this " miracle medicine" was in every household in America. Valuable enough to get caught in the crossfire during both World Wars...  And powerful enough to be studied by the founding members of a massive Big Pharma dynasty... There was nothing else like it on Earth. In fact, this miracle medicine was on track to become a game-changer for fighting the cancer epidemic. But then it just...disappeared. To this day, it's not being taught in medical schools--or prescribed in major U.S. cancer centers. But the results of lab studies are impressive. Big Pharma knows more about this than they're letting on...and these newly discovered documents prove it ... Everything you need to know is right here. To your health, Karen Reddel Logical Health Alternatives P.S. No one's talking about this--but this discovery is already changing the lives of cancer patients. See it here before corporate interests make it "disappear" again. This ad is sent on behalf of OmniVistaHealth, LLC. P.O. Box 913, Frederick, MD 21705, USA. If you would like to unsubscribe from receiving offers from OmniVistaHealth, please click here. | Advertisement | | Health News Roundup | Superbug crisis could get worse, killing nearly 40 million people by 2050, study estimates: By 2050, antibiotic-resistant superbugs could cause up to 10 million deaths annually if current trends continue, according to a new report. The study highlights the urgent need for global action to combat antibiotic resistance and improve infection control practices. | FDA expands approval of breast cancer drug Kisqali to earlier stage patients: The FDA has expanded the approval of the breast cancer drug Kisqali to include use in earlier stages of the disease, offering a new treatment option for patients with HR-positive, HER2-negative breast cancer. This expanded approval is based on promising results from clinical trials demonstrating Kisqali's effectiveness in reducing recurrence rates. | | Use of this email, website, and content is subject to the Privacy Policy and Terms of Use published on website. The information presented here is for general educational purposes only. MATERIAL CONNECTION DISCLOSURE: You should assume that the sender of this email has an affiliate relationship and/or another material connection to the persons or businesses mentioned in or linked to from this message and may receive commissions from purchases you make on subsequent web sites. You should not rely solely on information contained in this email to evaluate the product or service being endorsed. Always exercise due diligence before purchasing any product or service. This email contains Advertisements. |
|
No comments:
Post a Comment